Triple-Class Failure in HIV-Infected Patients

Abstract

Many patients treated before the availability of potent combination antiretroviral therapy (ART) developed resistance to multiple agents because of sequential monotherapy or dual therapy. How commonly do HIV-infected patients who initiate ART with ≥3 drugs develop extensive triple-class virologic failure (TCVF), defined as failure of multiple nucleoside reverse-transcriptase inhibitors (RTIs), of a nonnucleoside RTI, and of a ritonavir-boosted protease inhibitor (PI)? To find out, investigators studied an observational cohort of 7916 patients who initiated ART with ≥3 agents. The patients were …